Skip to main content
U.S. flag

An official website of the United States government

Naringin enhances CaMKII activity and improves long-term memory in a mouse model of Alzheimer’s disease

Bibliographic

Year of Publication:
2013
Contact PI Name:
Lian-Feng Zhang
Contact PI Affiliation:
Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medical Center, Peking Union Medical College, Beijing, China
Co-Authors:
Dong-Mei Wang, Ya-Jun Yang, Li Zhang, Xu Zhang, Fei-Fei Guan
Primary Reference (PubMED ID):
Funding Source:
Ministry of Science and Technology of China
Study Goal and Principal Findings:

The Amyloid-β (Aβ)-induced impairment of hippocampal synaptic plasticity is an underlying mechanism of memory loss in the early stages of Alzheimer’s disease (AD) in human and mouse models. The inhibition of the calcium/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation plays an important role in long-term memory. In this study, we isolated naringin from Pomelo peel (a Citrus species) and studied its effect on long-term memory in the APPswe/PS1dE9 transgenic mouse model of AD. Three-month-old APPswe/PS1dE9 transgenic mice were randomly assigned to a vehicle group, two naringin (either 50 or 100 mg/kg body weight/day) groups, or an Aricept (2 mg/kg body weight/day) group. After 16 weeks of treatment, we observed that treatment with naringin (100 mg/kg body weight/day) enhanced the autophosphorylation of CaMKII, increased the phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptor at a CaMKII-dependent site and improved long-term learning and memory ability. These findings suggest that the increase in CaMKII activity may be one of the mechanisms by which naringin improves long-term cognitive function in the APPswe/PS1dE9 transgenic mouse model of AD.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Naringin
Therapeutic Target:
Multi Target
Therapy Type:
Small Molecule
Therapeutic Agent:
Donepezil
Therapeutic Target:
Acetylcholinesterase

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57BL/6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Step-Through Passive Avoidance Test
Morris Water Maze
Biochemical
Calcium Calmodulin Kinase II (CAMKII)
phospho-Calcium Calmodulin Kinase II (phospho-CAMKII)
Glutamate Ionotropic Receptor AMPA Type Subunit 1 (GluR1)
phospho-Glutamate Ionotropic Receptor AMPA Type Subunit 1 (phospho-GluR1)
Immunochemistry
phospho-Calcium Calmodulin Kinase II (phospho-CAMKII)